TH 0059
Alternative Names: HSB-0059; TH-0059Latest Information Update: 23 Jan 2024
At a glance
- Originator Tharimmune
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Immunotoxins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jan 2024 Preclinical trials in Cancer in USA (Parenteral) (Tharimmune Pipeline, January 2024)
- 17 Jan 2024 Tharimmune plans IND-enabling studies in Cancer in USA in 2025 (Tharimmune Pipeline, January 2024)
- 13 Feb 2023 Hillstream Biopharma enters into an exclusive option agreement with Applied Biomedical Science Institute to license HER2 and HER3 Conformational Domain Bridging Epitopes technology